Otonomy Completes $45.9 Million Series C Equity Financing
SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it completed a Series C financing which raised $45.9 million in new funds. The investment was led by OrbiMed Advisors, LLC and new investors Aperture Venture Partners and Osage University Partners also participated. Existing investors Avalon Ventures, Domain Associates, Novo Ventures, RiverVest Venture Partners and TPG Biotech joined in the financing as well. Otonomy plans to use the financing to fund late-stage clinical trials for OTO-201 and OTO-104, development work to advance a third program to clinical trials and general corporate purposes.
(Logo: http://photos.prnewswire.com/prnh/20130806/MM59802LOGO)
The company also announced today that, in conjunction with the financing, Chau Q.Khuong has joined Otonomy’s board of directors. Mr. Khuong is private equity partner at OrbiMed and brings significant experience in private company operations as well as business development.
“We are pleased to have some of the world’s leading healthcare investors participate in this financing led by OrbiMed,” said David A. Weber, Ph.D., president and CEO of Otonomy. “Following the successful completion of clinical trials for both of our product candidates, Otonomy is now positioned to complete late-stage trials for both OTO-104 and OTO-201, and further expand our product pipeline.”
“Otic diseases remain underserved by the pharmaceutical industry and represent a significant unmet medical need with millions impacted each year in the U.S. alone,” said Mr. Khuong. “OTO-104 and OTO-201 along with the company’s proprietary technologies have established Otonomy as a leader in this field, and provide the opportunity for significant revenue generation and value creation.”
About Otonomy
Otonomy is a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the ear. Otonomy’s proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has two product candidates in clinical development. OTO-104 is a steroid that has completed a Phase 1b clinical trial in Meniere’s disease patients. OTO-201 is an antibiotic that has recently completed a Phase 1b clinical trial in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. Otonomy is advancing both OTO-104 and OTO-201 into late-stage clinical trials. Additional product candidates are expected to target tinnitus and chronic forms of hearing loss. For more information please visit: www.otonomy.com.
About OrbiMed
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector with approximately $7 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies on a worldwide basis, from venture capital start-ups to large multinational companies. OrbiMed’s team includes over 60 experienced professionals with offices in New York, San Francisco, Shanghai, Mumbai and Herzliya. OrbiMed manages a series of private equity funds, public equity funds, royalty and debt funds, and other investment vehicles.
Contact:
Westwicke Partners
Stefan Loren, Ph.D.
Managing Director
443.213.0507
sloren@westwicke.com
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
SOURCE Otonomy, Inc.
Help employers find you! Check out all the jobs and post your resume.
